iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Mankind Pharma Ltd Option Chain

2,205.6
(-0.49%)
Dec 3, 2025|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Ol (lots)Call PriceStrike PricePut PriceOl (lots)
1,8000%₹484.65 0%1,800--
1,350100%₹327 -5.31%1,900--
6750%₹319.75 0%1,950--
6750%₹234.55 0%2,000₹3.15 -10%45,000-9.90%
1,1250%₹204.15 0%2,050₹6.45 -12.83%9,90018.91%
21,600231.03%₹129.2 -19.04%2,100₹13.95 1.82%46,35052.59%
9,000207.69%₹90.1 -10.07%2,150₹25.6 4.7%73,12546.39%
72,225184.07%₹60.5 -10.96%2,200₹44 5.38%1,02,37516.66%
1,17,67540.59%₹37.8 -11.68%2,250₹70.1 7.02%1,01,0257.67%
1,93,7253.11%₹20.8 -15.95%2,300₹98 -1.55%51,300-0.43%
60,52581.75%₹11.5 -18.43%2,350₹125.25 0%4,2750%
64,57518.10%₹5.9 -20.8%2,400₹181 0%8,5500%
81,000-8.39%₹3.4 -15%2,450₹204.4 0%1,8000%
98,77511.13%₹2.05 -16.32%2,500₹253.95 0%9,9000%
1,1250%₹3 0%2,550--
1,1250%₹12.7 0%2,600₹348 0%3,3750%
--2,700₹460 0%2250%

Mankind Pharma: Related NEWS

Mankind Pharma Q1 Updates: Net profit down ~18%

The company also informed that its diluted earnings per share (EPS) slipped by 20.10% on a yearly basis to ₹10.60.

1 Aug 2025|01:41 PM
Read More
Top Stocks for Today - 01st August 2025

Here are some of the stocks that may see significant price movement today: Coal India, Mankind Pharma, Swiggy, etc.

1 Aug 2025|08:58 AM
Read More
Mankind Pharma posts mixed performance in Q4; stock slips ~4%

The business said that it logged a 10.70% year-on-year decline in its consolidated net profit at ₹420.80 Crore for Q4FY25.

22 May 2025|12:15 PM
Read More
Top Stocks for Today - 22nd May 2025

Here are some of the stocks that may see significant price movement today: NBCC, IndusInd Bank, Hindustan Zinc, etc.

22 May 2025|06:38 AM
Read More
Mankind Pharma Faces ₹183.11 Crore Tax Demand

The cumulative demand, including interest charges, is ₹183.11 crore.

30 Mar 2025|04:34 PM
Read More
Mankind Pharma Merges Three Subsidiaries

The merger took effect on March 29, 2025, after all necessary regulatory approvals were obtained.

30 Mar 2025|01:33 PM
Read More
Mankind Pharma Faces ₹111.68 Crore Tax Demand, Plans to Appeal

The tax adjustments pertain to Section 80IC/80IE, which involves deductions for businesses in special economic zones, and a disallowance of certain expenditures under Section 37(1) of the Act.

28 Feb 2025|11:13 PM
Read More
Top Stocks for Today - 24th January 2025

Here are some of the stocks that may see significant price movement today: Indus Towers, Dr Reddy’s Laboratories, Mankind Pharma, etc.

24 Jan 2025|07:50 AM
Read More
Mankind Pharma Q3 Profit Falls 16%, Revenue Jumps 24%

The company reported a good growth in EBITDA of 36.8% to ₹830 crore in the quarter against ₹606.5 crore in Q3 FY24.

23 Jan 2025|11:57 PM
Read More
Mankind Pharma Secures ₹5,000 Crore NCDs by Pledging 56.31% Stake in BSV

The NCDs issued are categorized, rated, secured, redeemable, and transferable, distributed across three series.

8 Jan 2025|04:01 PM
Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor), PFRDA Reg. No. PoP 20092018

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.